News and Updates

Clarity joins the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR)

The Australian-based clinical stage radiopharmaceutical company announces that it is now a member and will hold a Board position on the Council on Radionuclides and Radiopharmaceuticals, Inc (CORAR), a trade association and leading voice of the radionuclide and radiopharmaceutical industry in North America.

Clarity joins the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging

© Clarity Pharmaceuticals 2021 Australia

68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT

We compared the roles of 68Ga-FAPI-04 and 18F-FDG PET/CT in the evaluation of primary tumor and metastases in primary and recurrent breast cancer.

AUTHORS: Kömek, H., Can, C., Güzel, Y. et al.

SOURCE: Ann Nucl Med 35, 744–752 (2021).

© 2021 Springer Nature Switzerland AG

Regular production and supply of ready-to-use gallium-68 radiopharmaceuticals: centralized radiopharmacy concept with supply experience of 300 doses

Illustration of the feasibility of production and supply of ready-to-use 68Ga radiopharmaceuticals, similar to 18F-FDG, through a centralized production facility.

AUTHORS: Dheeraj Kumar, Anupam Mathur, Vrinda Prashant,

SOURCE: J Radioanal Nucl Chem 330, 83–90 (2021).

Two Tumors, One Target Preliminary Experience With 90Y-FAPI Therapy...

At progression of breast and colorectal cancers, FAPI PET/CT demonstrated positive tumor targeting in related metastases.  The patient was administered an experimental therapy with 90Y-FAPI46.,_One_...

AUTHOR: Rathke, Hendrik; Fuxius, Stefan; Giesel, Frederik L.; Lindner, Thomas; Debus, Jürgen; Haberkorn, Uwe; Kratochwil, Clemens

BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific for the Manufacture of TheraSphere™ Y-90 Glass Microspheres

BWXT Medical will invest to automate the production process at its Ottawa, Canada facility, and thereby significantly increase capacity and dependability to support a growing global demand for TheraSphere.

© 2021 Financial Post

Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

Theragnostics (Bracknell, UK and Braintree, MA) announces a global licensing agreement with Advanced Accelerator Applications (Saint-Genis-Pouilly, France) to develop and commercialize Gallium-68 one-step PET radiopharmaceuticals.

© 2021 Verizon Media

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

(published 2016) There has been a surge in the development of both diagnostics and therapeutics that take advantage of the expression and activity of PSMA/GCPII, which include gene therapy, immunotherapy, chemotherapy and radiotherapy. In this review, we discuss the biological roles that PSMA/GCPII plays, both in normal and diseased tissues, and the current therapies exploiting its activity that are at the preclinical stage.

Cancer-fighting nuclear medicine firms find home in central Indiana

Point Biopharma (Toronto, Canada), Science Research Corp.(Phoenix, AZ), SpectronRx (South Bend, IN), Curium (London & Paris), Novartis AG (Basel, Swiz.), Telix Pharmaceuticals (Melbourne, Australia) and Cardinal Health all establish facilities in Indiana.

Copyright © 2021 All Rights Reserved, Indianapolis Business Journal